Skip to main content

Nonoperative Management of Rectovaginal Fistula

Nonoperative management of rectovaginal fistula (RVF) consists of observation with local care, symptom control, drainage, treatment of the underlying disease and, in selected patients, fecal diversion. It can precede or accompany repair. Seton placement and fecal diversion are procedural or surgical adjuncts and not medical treatments. Their purpose may be drainage or symptom relief.

See Rectovaginal Fistula, ERAF ± Sphincteroplasty and Fecal Diversion for evaluation and operative options.

Conservative care and reassessment​

ASCRS 2022 supports initial nonoperative care for most obstetric RVFs and selected benign, minimally symptomatic fistulas (2C). A period of 3–6 months is typical in suitable patients. The ASCRS-cited 52–66% range comes from selected reports with mixed etiologies and differing endpoints. Symptoms and tissue recovery determine when to reassess, and no waiting period is mandatory.[1]

MeasurePurpose
Sitz bathsPerineal hygiene and comfort
Local wound careGentle cleansing; keep the perineum clean and dry
DebridementRemoval of necrotic tissue at the fistula site when needed
AntibioticsTreatment of clinical infection (cellulitis, abscess, purulent drainage); not routine
Stool-bulking fiber and softenersFormed soft stools reduce mechanical trauma to the tract and avoid straining

The best candidates are those with a small, low obstetric RVF, an acute or early presentation, minimal symptoms, no sphincter defect and no active Crohn's disease or radiation injury. This candidate profile is conventional teaching that extends the guideline's indication, and no series tests it directly.

A small opening can coexist with a deeper infected cavity. Worsening pain, fever or suspected abscess requires prompt assessment and source control; observation is not a reason to postpone drainage. Suspected malignancy requires diagnosis and an oncologic plan before choosing a benign fistula repair.[1][2]

Drainage and setons​

A loose draining seton may facilitate resolution of acute inflammation or infection associated with RVF; ASCRS grades this 1C . It may help prevent a septal abscess in a narrow tract, a small vaginal opening or multiple tracts, and provide longer-term symptom relief when repair is unsuitable. It is not required for every RVF and may leave ongoing drainage.[1]

Multidisciplinary examination under anesthesia can clarify the tract, associated defects and rectal disease. A published technical demonstration describes curettage of the tract followed by seton placement. In the usual technique the tract is probed, and a vessel loop or silastic seton is passed from the rectal to the vaginal opening and tied loosely. The demonstration reports no comparative closure rate.[3] In Sonoda's retrospective advancement-flap cohort of 99 followed patients (62 anorectal and 37 rectovaginal fistulas), prior seton placement was associated with healing (P = 0.025). A seton primarily controls drainage.[13][1]

A seton serves as a bridge to repair when it relieves edema, inflammation and infection, and as long-term symptom control when repair is unsuitable. It suits a narrow tract with a small vaginal opening, multiple tracts, or an inflammatory or neoplastic process that needs treatment before repair.[1]

Crohn's disease: control sepsis and inflammation​

Coordinate colorectal surgery, gastroenterology and urogynecology. Drain infection when present, assess rectal inflammation and strictures, and optimize medical treatment. Control of proctitis is important before elective closure; it is not a prerequisite for urgent abscess drainage. ECCO 2024 suggests medical treatment and consideration of surgical closure in selected anogenital or rectogenital fistulas; the specific supporting evidence is low level.[4]

ACG 2025 notes that internal fistulas, including RVF, have limited trial evidence. Infliximab with or without an immunomodulator is commonly used before selected repair; the guideline does not require an immunomodulator for every patient. Drug selection, safety screening, dosing and monitoring belong in a gastroenterology-directed plan.[2]

Distinguish RVF evidence from perianal-fistula evidence​

EvidenceWhat it supports—and its limits
ACCENT II main trialIn 306 adults with draining abdominal or perianal fistulas, infliximab 5 mg/kg was given at weeks 0, 2 and 6, and responders were randomized to placebo or 5 mg/kg every 8 weeks. Median time to loss of response was more than 40 weeks with infliximab versus 14 weeks with placebo (P < 0.001). Among induction responders in the week-54 comparison, 33/91 assigned maintenance infliximab (36%) versus 19/98 assigned placebo (19%) had no draining fistulas (P = 0.009). Most fistulas in the trial were perianal.[12]
ACCENT II RVF post hoc analysisTwenty-five women had 27 draining RVFs at baseline. After infliximab induction (weeks 0, 2 and 6), 17/28 evaluated fistulas were closed at week 10 (60.7%) and 13/29 at week 14 (44.8%); the evolving denominators count fistulas, not women. Among the subset of patients who had responded to induction, 13/18 of their fistulas (72.2%) were no longer draining at week 14 — the same week-14 closures counted against a responders-only denominator, not an additional cohort. Median closure duration was 46 weeks with maintenance infliximab versus 33 with placebo.[5]
AGA 2021, active perianal fistulaRecommends infliximab; suggests adalimumab, ustekinumab or vedolizumab. In patients without a perianal abscess, it recommends a biologic plus an antibiotic over biologic alone and suggests against antibiotics alone.[6]
Seton plus medical therapyDrainage and biologic treatment are complementary when sepsis is present. The ASCRS discussion reports that a subgroup analysis of two randomized anti-TNF-versus-placebo trials with follow-up beyond 4 weeks found complete fistula healing of 46% versus 13% and 30% versus 13%, respectively; a meta-analysis of all four trials found no difference in complete or partial fistula healing. It concerns anorectal Crohn's fistulas.[1]

Antibiotics can treat infection and may be adjunctive to biologics. An abscess generally needs drainage.[2]

Fecal diversion: a separate decision​

Diversion may help manage an anastomotic complication, substantial contamination, severe refractory Crohn's disease or distressing symptoms. It reduces fecal contamination of the tract as a bridge to repair, offers palliation for patients who are poor surgical candidates or decline repair, and can accompany a planned repair. In severe refractory perianal Crohn's disease, diversion may improve symptoms but bowel restoration remains uncertain. A 2025 meta-analysis included 17 studies (714 adults); pooled clinical improvement was 65% in 12 studies (397 patients), bowel restoration was 29% in 16 studies (628 patients), and proctectomy or proctocolectomy was 37% in 14 studies (613 patients), with median follow-up of 58.2 months.[14] ASCRS lists diversion as the initial step for RVFs after colorectal anastomotic complications, but selected patients may instead require reoperation and reconstruction, so no single pathway applies.[1][2]

In Obi's 2026 retrospective cohort, 158 women underwent 424 procedures: 100 were diverted and 58 were not. Five-year estimated cure was 72.7% versus 64.3% (P = .38). Patients with repeated repairs were more likely to be diverted.[7]

For radiation-associated RVF, diversion can relieve symptoms without closing the fistula. Selected restorative resections or permanent diversion require separate assessment of morbidity and function; see Transabdominal RVF Repair.

Adjuncts with limited evidence​

  • Fibrin glue and plugs: ASCRS excludes them from its RVF repair recommendations because reported results are poor.[1] A historical glue series healed 4/5 RVFs, but only 6/10 fistulas overall.[8]
  • Pessary-associated RVF and vaginal estrogen: remove the implicated pessary and reassess the erosion. A 2025 review of 76 mixed urogenital and rectovaginal pessary-associated fistulas found size reduction or resolution with conservative care in 69%.[15] In one RVF case, pessary removal and estradiol were combined.[9] Treating symptomatic atrophy is a separate goal from claiming that estrogen closes a fistula.
  • Experimental healing strategies: a menopausal-rat vaginal-injury study found different epithelial and stromal responses to postoperative estrogen.[10] Microbiome-directed fistula treatment remains investigational.[11]

Approach by etiology​

EtiologyFirst nonoperative approachConsideration
ObstetricLocal care, fiber and antibiotics for infection; consider a seton when drainage is neededSelected fistulas may heal during initial nonoperative care; the ASCRS-cited 52–66% range combines differing etiologies and endpoints.[1]
Crohn's diseaseDrain infection; consider a draining seton when local sepsis or tract drainage needs control, with gastroenterology-directed therapyAssess rectal inflammation and stricture before elective closure.[1][4]
AnastomoticFecal diversion is generally the initial step to reduce acute inflammation and symptomsSelected immediate or early postoperative fistulas may instead be better served by reoperation and repeat colorectal anastomosis; persistent fistulas may need reconstruction.[1]
RadiationMedical optimization; consider fecal diversion for symptom relief or as part of repairPoor tissue quality; diversion alone may not close the fistula, and selected complex cases may require flap interposition, resection or permanent diversion.[1]
Minimally symptomatic benignConservative wound careLimited data; repair if the fistula persists

When to move to repair​

Elective repair is considered when persistent drainage or functional burden outweighs continued conservative care, after the cause, infection, tissue quality and patient preferences are addressed. Persistent fistula after a suitable 3–6-month trial, disabling vaginal passage of stool or flatus, or recurrent infection prompts reassessment for repair. An uncontrolled abscess requires further drainage and source control before elective closure; suspected malignancy requires diagnosis and an oncologic plan before benign fistula repair.[1] In Crohn's disease, repair follows control of rectal inflammation without anorectal stricture. Closure, continence, sexual function and the possibility of retaining a stoma are discussed separately.[1][2]

References​

1. Gaertner WB, Burgess PL, Davids JS, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2022;65(8):964–985. doi:10.1097/DCR.0000000000002473

2. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2025;120(6):1225–1264. doi:10.14309/ajg.0000000000003465

3. Muñoz JM, Levin PJ, Saur NM, Cox CK. Multidisciplinary approach to evaluation of rectovaginal fistulas. Am J Obstet Gynecol. 2024;231(2):285–286. doi:10.1016/j.ajog.2024.04.029

4. Adamina M, Minozzi S, Warusavitarne J, et al. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. J Crohns Colitis. 2024;18(10):1556–1582. doi:10.1093/ecco-jcc/jjae089

5. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912–920. doi:10.1016/S1542-3565(04)00414-8

6. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021;160(7):2496–2508. doi:10.1053/j.gastro.2021.04.022

7. Obi M, Kanters A, Spivak AR, et al. Determinants of fecal diversion prior to rectovaginal fistula surgery. J Gastrointest Surg. 2026:102442. doi:10.1016/j.gassur.2026.102442

8. Abel ME, Chiu YS, Russell TR, Volpe PA. Autologous fibrin glue in the treatment of rectovaginal and complex fistulas. Dis Colon Rectum. 1993;36(5):447–449. doi:10.1007/BF02050009

9. Cichowski S, Rogers RG. Nonsurgical management of a rectovaginal fistula caused by a Gellhorn pessary. Obstet Gynecol. 2013;122(2 Pt 2):446–449. doi:10.1097/AOG.0b013e31828aec98

10. Ripperda CM, Maldonado PA, Acevedo JF, et al. Vaginal estrogen: a dual-edged sword in postoperative healing of the vaginal wall. Menopause. 2017;24(7):838–849. doi:10.1097/GME.0000000000000840

11. Satora M, Żak K, Frankowska K, et al. Perioperative factors affecting the healing of rectovaginal fistula. J Clin Med. 2023;12(19):6421. doi:10.3390/jcm12196421

12. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876–885. doi:10.1056/NEJMoa030815

13. Sonoda T, Hull T, Piedmonte MR, Fazio VW. Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. Dis Colon Rectum. 2002;45(12):1622–1628. doi:10.1007/s10350-004-7249-y

14. Hartley I, Sarraf B, Wilding H, Segal JP, Ding NS. "Outcomes of fecal diversion in perianal Crohn's disease: a systematic review and meta-analysis." J Dig Dis. 2025;26(5-6):180–192. doi:10.1111/1751-2980.13354

15. Curtis TJ, Chant C, Quek S, Giarenis I, Gray TG. "Fistulae secondary to vaginal pessary use for pelvic organ prolapse: a systematic review." Int Urogynecol J. 2025;36(3):491–521. doi:10.1007/s00192-024-06035-4